AI Now Accelerates Diagnosis of Rare Diseases Affecting 300 Million People

The utilisation of Artificial Intelligence (AI) and genetic sequencing (genomics) technologies is now the primary solution in breaking the chain of the “rare disease paradox” that affects more than 300 million people worldwide. Data from the World Health Organization (WHO) indicates that although each type of rare disease affects only a small number of individuals, collectively the number of sufferers reaches six times the total cancer patients over the past five years. The main challenge of rare diseases lies in the difficulty of diagnosis, where 80% of cases have complex genetic components. In response, Genomics England is collaborating with Amazon Web Services (AWS) and Illumina to accelerate disease confirmation processes through the integration of genetic analysis and AI technology. This programme is a development from the 100,000 Genomes Project, which now forms the foundation for the Genomic Medicine Service (GMS) in the NHS. Thanks to the success of that project, the NHS has officially become the world’s first national health system to offer whole genome sequencing as part of routine medical care. As reported by MobiHealthNews, at the HIMSS 2026 conference in Las Vegas, Dr Rowland Illing, Chief Medical Officer at Amazon Web Services (AWS), explained that although the role of AI is becoming increasingly dominant, Illing emphasised the importance of human oversight in medical processes. “Our view is that there must always be human oversight, and the goal of all these agents is to take low-level work away from humans, so that human relationships can be maintained,” said Dr Illing. The implementation of AI is also beginning to show real results in child health. The National Children’s Hospital in the United States has developed AI technology capable of analysing facial features of infants through smartphone cameras. This system can detect subtle changes that signal rare genetic disorders, thereby preventing misdiagnoses that often persist for years. Dr Matthew Bainbridge, lead researcher at Rady Genomics, stated that this technology is key to achieving medical access equity. “Utilising AI and cloud computing is a critical step as we strive to make genetic testing more equitable, affordable, and widely available,” he emphasised. In addition to AI, the healthcare industry is also turning to quantum computing to accelerate drug molecule simulations. With large-scale data processing, this technology is expected to reduce the costs of genetic therapy production, making rare disease treatments more affordable.